The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
作者信息
Dowell Jonathan E, Minna John D
机构信息
Dallas Veterans Affairs Medical Center, TX, USA.
出版信息
Nat Clin Pract Oncol. 2004 Nov;1(1):2-3. doi: 10.1038/ncponc0007.
PMID:16264773
Abstract
摘要
相似文献
1
The impact of epidermal-growth-factor-receptor mutations in response to lung-cancer therapy.
Nat Clin Pract Oncol. 2004 Nov;1(1):2-3. doi: 10.1038/ncponc0007.
2
EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
N Engl J Med. 2005 Jul 14;353(2):207-8. doi: 10.1056/NEJM200507143530217.
3
Medicine. Why a new cancer drug works well, in some patients.
Science. 2004 Apr 30;304(5671):658-9. doi: 10.1126/science.304.5671.658a.
4
Modern treatment of lung cancer: case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib.
J Clin Oncol. 2005 Oct 20;23(30):7736-8. doi: 10.1200/JCO.2005.02.4760.
5
Unusual cases in multiple myeloma and a dramatic response in metastatic lung cancer: case 4. Mutation of the epidermal growth factor receptor in an elderly man with advanced, gefitinib-responsive, non-small-cell lung cancer.
J Clin Oncol. 2005 Jan 1;23(1):235-7. doi: 10.1200/JCO.2005.07.169.
6
Gefitinib. Still no convincing results in non-small cell lung cancer.
Prescrire Int. 2010 Jun;19(107):113.
7
Epidermal growth factor receptor mutations predict sensitivity to gefitinib in patients with non-small-cell lung cancer.
Future Oncol. 2005 Aug;1(4):461-6. doi: 10.2217/14796694.1.4.461.
8
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib.
Clin Cancer Res. 2006 Oct 1;12(19):5764-9. doi: 10.1158/1078-0432.CCR-06-0714.
9
Supersensitive mutation: two case reports of non-small-cell lung cancer treated with epidermal growth factor receptor tyrosine kinase inhibitors.
Clin Lung Cancer. 2010 Sep 1;11(5):E5-8. doi: 10.3816/CLC.2010.n.047.
10
Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib.
J Clin Oncol. 2006 Sep 20;24(27):4517-20. doi: 10.1200/JCO.2006.06.6126.
引用本文的文献
1
Cancer Therapy Guided by Mutation Tests: Current Status and Perspectives.
Int J Mol Sci. 2021 Oct 10;22(20):10931. doi: 10.3390/ijms222010931.
2
Translational research in oncology--10 years of progress and future prospects.
Nat Rev Clin Oncol. 2014 Nov;11(11):649-62. doi: 10.1038/nrclinonc.2014.158. Epub 2014 Oct 7.
3
PIK3CA mutation is an oncogenic aberration at advanced stages of oral squamous cell carcinoma.
Cancer Sci. 2006 Dec;97(12):1351-8. doi: 10.1111/j.1349-7006.2006.00343.x.
Zotero 插件